BEHAVIORAL EVALUATION OF IMIPRAMINE AND NIALAMIDE IN REGRESSED SCHIZOPHRENIC PATIENTS WITH DEPRESSIVE FEATURES
CARL A. LEUTHOLD PH.D.1,
F. J. BRADSHAW JR. M.D.2,
G. W. ARNDT M.D.3,
E. F. HOFFMAN M.D.4, , and
VLADIMIR PISHKIN PH.D.5
1 Chief, Psychology Service; Veterans Administration Hospital, Tomah, Wisconsin.
2 Director, Professional Services; Veterans Administration Hospital, Tomah, Wisconsin.
3 Staff Psychiatrist; Veterans Administration Hospital, Tomah, Wisconsin.
4 Staff Physician; Veterans Administration Hospital, Tomah, Wisconsin.
5 Director, Research Laboratory, Veterans Administration Hospital, Tomah, Wisconsin.
Imipramine and nialamide were found to be comparable as measured by psychiatrist's clinical ratings of over-all improvement in patients with depressive symptoms. On measures of specffic behavioral factors on the MACC scale the two drug groups were differentiated by improved motility in patients on imipramine and by positive changes in affect in patients receiving nialamide during the first 6 weeks of drug administration.
